It’s a rally. It’s a sell-off. At the end of the week, the only thing that was clear was confusion. Investors were hoping to get clarity with the U.S. midterm elections behind them. Instead, they got more volatility.
The reason is uncertainty about future regulation surrounding data centers. The conventional wisdom suggests it may not be as bad as the worst-case scenario. But any regulation is likely to slow down a trade that looked like a runaway train.
That’s likely to mean the flight to safety will continue. A strong jobs report on Friday raised the odds for the Federal Reserve to raise interest rates in December. Dividend payers may still appeal to investors seeking income, particularly those that offer a yield above the current rate of inflation.
Speaking of inflation, next week investors will get the latest reading on inflation at the consumer and producer levels. A hot number from either report will likely cement expectations for higher rates and will likely keep volatility front and center.
Articles by Thomas Hughes
AbbVie NYSE: ABBV hit a fresh high after an earnings beat and a dividend increase. But Thomas Hughes said the Humira era is fading, and he explained why its new growth engines face another test.
Oracle NYSE: ORCL may be nearing the peak of its AI spending cycle. Hughes explained what that could mean for a stock recovery.
Tempus AI NASDAQ: TEM surged on a beat-and-raise quarter, but analysts reacted with caution. Hughes explained what needs to happen for the rally to last.
Articles by Sam Quirke
Apple NASDAQ: AAPL beat estimates, but the stock sold off amid concerns about memory and AI spending. Sam Quirke pointed out the catch for investors heading into the holiday quarter.
Qualcomm NASDAQ: QCOM beat earnings, but soft guidance sent shares lower. Quirke explained why its fastest-growing businesses come with a catch.
Amazon NASDAQ: AMZN has already erased its post-earnings sell-off despite concerns over the impact of capital expenditures (CapEx) on free cash flow. Quirke asked whether the biggest opportunity is still ahead.
Articles by Chris Markoch
Marriott NASDAQ: MAR topped earnings estimates as fee growth outpaced room revenue. Chris Markoch explained why the stock is more than a bet on travel demand.
Two oil majors just reported, and the message was straightforward. Blue-chip stocks still work. Markoch pointed out why their results remind investors to keep it simple.
Palantir NASDAQ: PLTR delivered a $2.3 billion quarter, but the stock dipped after earnings. Markoch analyzed how the results put its premium valuation to the test.
Articles by Ryan Hasson
Starbucks NASDAQ: SBUX says its turnaround is done, and the numbers back it up. But Ryan Hasson explained the one catch investors shouldn’t overlook.
Big Tech is spending billions on AI, and someone is cashing those checks. Hasson highlighted five stocks that are getting paid.
Search growth is slowing at Alphabet NASDAQ: GOOGL, raising questions about how it will monetize AI. Hasson asked whether those fears are warranted.
Articles by Leo Miller
Marvell Technology NASDAQ: MRVL fell 13% on a report that it may acquire Lumentum NASDAQ: LITE. Leo Miller explained why markets are weighing the price tag of an optical swing for the fences.
CEOs at three underperforming companies just made notable trades in their own stock. Miller explained what those insider moves could signal.
Meta Platforms NASDAQ: META is planning a $100 billion push to fund its AI buildout. Miller showed why that plan has a catch for existing shareholders.
Articles by Nathan Reiff
Investors looking to play the weight-loss drug boom have more than one ETF option. Nathan Reiff compared a GLP-1-focused fund with one offering broader peptide exposure.
Waste services aren’t usually thought of as growth plays. Reiff highlighted three stocks with more growth than you might expect.
JFrog NASDAQ: FROG is pulling ahead of its software rivals in the AI race. Reiff explained why it could be the infrastructure company to beat.
Articles by Dan Schmidt
One waste giant has the momentum, while the other offers a safer dividend. Dan Schmidt explained which advantage matters more for investors.
Uranium prices are near historic highs, but Cameco NYSE: CCJ missed earnings. Schmidt explained why the stock hasn’t followed the commodity higher.
Investors are rotating away from AI after the election. Schmidt highlighted three dividend ETFs that offer different ways to navigate the sell-off.
Articles by Jeffrey Neal Johnson
Energy Transfer TXSE: ET missed earnings estimates. But Jeffrey Neal Johnson pointed out why the miss may be hiding its strongest advantage.
TeraWulf NASDAQ: WULF just landed a $19 billion deal backed by Google. Johnson provided a breakdown of why that credit backstop may be its biggest advantage.
Freeport-McMoRan NYSE: FCX is betting $4.5 billion on a major copper expansion. Johnson explained what the project means for its long-term growth.
Before you consider AbbVie, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and AbbVie wasn’t on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
